This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAINT LAURENT, Quebec, Dec. 11, 2012 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (the "Company") today announced that Rajiv Khosla RPh, PhD, MBA has joined its management team in a senior consulting capacity effective January 1, 2013.
"I am very proud and excited to welcome Rajiv to our management team," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "Rajiv brings a wealth of experience and expertise from a distinguished career in the pharmaceutical industry." That experience includes VP Business Development at Biovail Corporation; VP and General Manager, Pharmaceutical, at Sensient Technologies, and Senior Business Director, Healthcare, at ICI Group.
"Dr. Khosla's business development experience and record of leading growth in the sector are key assets as IntelGenx moves forward," Dr. Zerbe said, noting that Dr. Khosla also has deep knowledge in drug delivery systems.
Initially, Dr. Khosla will assist IntelGenx with strategic operations, business development activities and provide advice related to IntelGenx' current and future pharmaceutical project development. He will also play an important role in the Company's ongoing succession planning. It is expected that on April 1, 2013, Dr. Khosla will be appointed to the newly created positions of Chief Operating Officer and Chief Scientific Officer at IntelGenx, subject to successful attainment of Canadian work permit documents.
Dr. Khosla has served as a member of the IntelGenx Board of Directors, where Dr. Zerbe said it became clear that his contributions to the future of the Company could be very significant. He will resign his board seat as he begins his new role.
Most recently, Dr. Khosla was President, Chief Executive Officer and a member of the board of directors of Orasi Medical, a leading provider of clinical neurophysiology biomarkers, focused on the industrialization and standardization of magnetoencephalography (MEG) in central nervous system drug and therapeutic device development. In January 2011, Dr. Khosla founded CEUTEC LLC, a private company that offers a full-service of business development activities to Biotech, Specialty Pharma and Venture Capital/Private Equity Firms.